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Introduction
The modulatory role of the γ-aminobutyric acid (GABA) system, mainly GABA B receptors, has recently been related to addiction. Numerous observations indicate that the tonic activation of GABA B receptors abolishes the reinforcement effects of morphine, cocaine, and ethanol (Brebner et al., 2002; Filip et al., 2007; Maccioni et al., 2008) . However, selective antagonists of these receptors did not alter the dose range of intravenously self-administered cocaine (Filip et al., 2007) or the expression of morphine-induced place preference (Tsuji et al., 1996) . The role of increased dopamine in the nucleus accumbens in rewarding and locomotor effects of several drugs of abuse are well established (Koob and Bloom, 1988) . Some evidence suggests the involvement of GABA B receptor in controlling dopamine efflux in the nucleus accumbens: the systemic administration of baclofen, a selective GABA B receptor agonist, decreased nucleus accumbens dopamine efflux in rats trained to self-administer amphetamine (Brebner et al., 2005 ) by a mechanism involving the stimulation of GABA B receptors located on cell bodies in ventral tegmental area (VTA) dopamine neurons that project to the nucleus accumbens (Liang et al., 2000) .
Numerous preclinical and clinical studies have demonstrated that GABA B receptor agonists suppress ethanol-related behaviors (Addolorato et al., 2000 (Addolorato et al., , 2002 Bechtholt and Cunningham, 2005; Colombo et al., 2000 Colombo et al., , 2002 Colombo et al., , 2003a Colombo et al., , 2003b Knapp et al., 2007; Heilig and Egli, 2006; Maccioni et al., 2005 Maccioni et al., , 2008 Moore and Boehm, 2009; Walker and Koob, 2007) . For example, in rats, baclofen inhibited the acquisition of ethanol consumption and the ethanolinduced conditioned place preference, decreased ethanol-induced motivational properties and withdrawal symptoms (such as anxiety-related behaviors), promoted abstinence, increased ethanol intake in a drinking-in-the-dark procedure, and reduced ethanol consumption in Sardinian ethanol-preferring rats. Although most data have shown that baclofen suppresses ethanol consumption, few studies in animals have reported that specific doses of baclofen increased ethanol selfadministration (Czachowski et al., 2006; Petry, 1997) and ethanol intake (Smith et al., 1992 (Smith et al., , 1999 . Although ethanol consumption was increased in C57BL/6J mice after repeated baclofen administration in the drinkingin-the-dark procedure (Moore et al., 2007) , when microinjection of baclofen was administered into the anterior ventral tegmental area a reduced binge-like ethanol intake was observed in the same strain (Moore and Boehm, 2009) . In humans, a recent clinical study reported no effect of baclofen treatment on ethanol consumption (Garbutt et al., 2010) , although recently Muzyk et al. (2012) reported that patients treated with baclofen experienced higher rates of abstinence and lower anxiety scores.
Our previous study showed that the genes that encode the GABA B1 and GABA B2 subunits (Gabbr1 and Gabbr2, respectively) were differentially expressed only in mice that continued consuming ethanol in large quantities even when adding quinine to ethanol solutions (named here as "loss of control" mice or group A) using this same three-bottle free-choice paradigm (Ribeiro et al., 2010 (Ribeiro et al., , 2012 . Only mice classified as group A showed increased Gabbr1 and Gabbr2 transcription levels in cerebral areas proposed to be related to drug taking and drug seeking (Kalivas and Volkow, 2005; Everitt and Robbins, 2005) suggesting that these genes may be related to ethanol addiction.
Considering that (i) GABA B receptors appear to be involved in ethanol related behaviors, (ii) some discrepancies have been reported in the literature concerning the relationship between GABA B receptors and ethanol consumption, (iii) differences in Gabbr1 and Gabbr2 transcription levels were found in mice with different ethanol intake phenotypes, and (iv) our validated ethanol consumption model provides an alternative approach to the study of addictive behaviors, the present study investigated the effect of baclofen treatment on ethanol consumption in mice with different intake profiles.
Material and methods

Animals
Seventy locally bred, naive, male Swiss mice weighing 20-30 g and aged 45 days at the beginning of the experiment were housed individually in cages measuring 20×30×20 cm in a temperature-controlled room (22±2°C) maintained on a 12 h/12 h light/dark cycle (lights on at 0700 h). Food was available ad libitum (Purina Laboratories, Brazil). The animals were weighed weekly. The experiment began after a 1-week acclimation period. All animal maintenance, care, and treatment procedures were controlled and approved by the Ethics Committee for Animal Experimentation of the Setor de Ciências Biológicas, Universidade Federal do Paraná (process no. 23075.105451/2009-19; approved November 10, 2009 ).
Drugs
Ethanol solutions (10% and 5%, v/v) were prepared for oral administration by diluting ethanol P.A. (Vetec Laboratories, Bronx, NY, USA) with tap water every other day (to control for ethanol evaporation). Adulterated ethanol solutions were prepared with 0.005 g/L of quinine hydrochloride. Baclofen hydrochloride solutions (RBI, Natick, MA, USA) were prepared for intraperitoneal administration by diluting with saline (0.1 mL/10 g).
Experimental design
Extended chronic ethanol intake
A group of mice (n = 60) had 24 h access to three bottles (inverted 25 mL graduated cylinder with sipper tube) containing 10% and 5% (v/v) ethanol and tap water for 10 weeks (acquisition phase, AC). Over the next 2 weeks, mice were submitted to four cycles of ethanol withdrawal (withdrawal phase, W), consisting each cycle of 2 days with access to water (W1, W2, W3 and W4) followed by 2-day free access to ethanol solutions and water (aW1, aW2 and aW3). For the following 2 weeks, they again had free access to the ethanol solutions and water (reexposure phase, RE). At the end of this period, the ethanol solutions were adulterated with quinine and offered to the animals for a further 2-week period (adulteration phase, AD). The quinine concentration (0.005 g/L) was chosen based on dose-response curve data previously performed in our lab (Fachin-Scheit et al., 2006) and recently confirmed by us (data not shown here). The analysis of the dose-response curves showed that 0.005 g/L reduced significantly the water intake when quinine was added without causing a total inhibition of intake, while higher concentrations (0.01 and 0.05 g/L) caused totally inhibition, i.e. a ceiling effect The positions of the bottles were changed on alternate days when the fluid intake was measured volumetrically. A separate group of ethanol naive control animals (n = 10) only had access to water. At the end of the exposition to the 3-bottle free choice paradigm, the mice were classified into groups based on their individual patterns of ethanol preference and consumption. Firstly, we evaluated the preference between total ethanol intake (mL) and water consumption during each phase for each mouse. Those mice preferring water during all phases were classified as "light-drinker" (group L). Those mice preferring ethanol during AC were, then, evaluated regarding their individual ethanol consumption (g/kg/day) along the phases: those ones maintaining [i.e., no significant decrease] the ethanol intake when ethanol solutions were added quinine (AD phase) were classified as "loss of control" (group A); and those ones with decreased ethanol consumption during the AD phase compared to AC phase were classified as "heavy-drinker" (group H). The animals that did not conform strictly to any of these patterns were excluded from subsequent analyses.
Baclofen treatment
Firstly, we assessed the effect of baclofen on the ambulation in open field test in the dose range of 0.6-10.0 mg/kg (dose-response curve). Naïve male Swiss mice (15/dose) received acutely i.p. injections of baclofen (0.6; 1.25; 2.5; 5.0 or 10.0 mg/kg) or saline 30 min before their exposition to the open field test accordingly to the methodology described by Boerngen-Lacerda and Souza-Formigoni (2000) . Each animal was placed in the center of the arena and its ambulation in the central area and in the peripheral area (number of squares invaded) was recorded for 5 min. From the obtained curve we chose the three doses used to treat the classified groups.
After the last day of the AD phase, the animals spent 4 days in abstinence, with access only to water. After the classification of mice, they were randomly distributed to receive either: (I) baclofen (each animal received i.p. injections of all doses of baclofen: B1.25 = 1.25 mg/kg, B2.5 = 2.5 mg/kg, B5.0 = 5.0 mg/kg) or (II) saline (SAL; each animal received i.p. saline injections during the period of baclofen treatment). Each animal assigned to the baclofen treatment (I) received all baclofen doses administered using a Latin square design. Each dose was administered twice on 2 consecutive days, and mice had free access to ethanol and water. Between the administrations of the different doses, an interval of 4 days was given, during which the animals had access only to water. The salinetreated mice (II) were subjected to the same conditions and the same experimental design as the baclofen-treated groups, except the baclofen treatment. Access to the solutions of ethanol and water (free-choice) was allowed 30 min after the injection of baclofen or saline. Ethanol and water consumption was then quantified after 24 h of the injection. The 10 animals from the ethanol naive control group were randomly distributed into two groups designated to receive the same doses of baclofen and then to have access only to water (III) or to 3-bottle free choice (IV). The procedure (I) was designed to assess the baclofen effect on ethanol intake in each different intake-profile group; the procedure (II) to assess the saline effect on ethanol intake in each different intake-profile group; the procedure (III) to assess the baclofen effect on water intake in a control group and the procedure (IV) to assess the baclofen effect on initial ethanol intake in a control group.
Statistical analysis
Data were analyzed for distribution normality using the KolmogorovSmirnov test and homogeneity of variance using Levene's test. Body weight in grams and ethanol intake in milliliters were used to compute the grams of ethanol intake per kilogram of body weight (g/kg). Ethanol and water consumption were expressed as the daily median and lower and upper quartiles. To classify each mouse accordingly to its ethanol intake pattern we considered the individual preference between total ethanol intake (mL) and water intake and also, the individual ethanol consumption in g/kg/day in each phase: firstly, the preference between water and total ethanol intake (mL) in each phase was detected through Mann-Whitney test for each mouse, then, a Friedman analysis with repeated measures followed by the multiple comparison test for each animal to compare individual consumption throughout the phases by considering the daily consumption for each phase (i.e., 20 measures in the AC phase, 9 measures in the RE phase, and 10 measures in the AD phase). After the classification of mice into three groups (A, H, and L), the Kruskal-Wallis and Friedman analyses followed by the multiple comparison test were used to compare, respectively, the groups and phases for ethanol consumption. Additionally, the Kruskal-Wallis test followed by the multiple comparison test was used to compare groups and baclofen doses for ethanol consumption during the baclofen treatment period. All analyses were performed using Statistica 6.1 software (StatSoft, Sao Caetano do Sul, Brazil). Differences were considered significant at p ≤ 0.05.
Results
Extended chronic ethanol intake
Group classification based on individual consumption
The analysis of the individual patterns of ethanol consumption in the different phases and the use of the criteria established in the Methods above enabled the classification of the mice into three groups: group A (n = 11), group H (n = 11), and group L (n = 16). Additionally, three mice died and nineteen did not conform to the criteria for classification. Therefore, these mice were excluded from the subsequent analyses (for a more detailed description of the classification procedure, see our previous validation study in FachinScheit et al., 2006) . For illustration, examples of each consumption profile are shown in Fig. 1 , A: "loss of control" mouse; B: "heavydrinker" mouse; C: "light-drinker" mouse.
Intergroup consumption analysis
In Fig. 2 the ethanol consumption during each phase and cycle (AC, aW1, aW2, aW3, RE and AD phases) for each group can be seen. The Friedman analysis of variance (ANOVA) performed for ethanol consumption in each group revealed a statistically reliable main effect of phase in group A (χ 2 (5, 11) =38.90, pb 0.001); in group H (χ 2 (5, 11) =48.97, pb 0.001) and in group L (χ 2 (5, 16) =75.52, pb 0.001). The multiple comparison analysis showed that group A maintained the same pattern of ethanol consumption during the AC and AD phases (p> 0.05), whereas groups H and L decreased their ethanol consumption in the AD phase compared with the AC phase (pb 0.001 and pb 0.01, respectively). After the first withdrawal phase cycle (aW1), groups A and H maintained the same pattern of ethanol consumption as the AC phase (p>0.05), whereas group L increased its consumption (pb 0.001). After the second and third withdrawal cycles (aW2 and aW3) and in the RE phase, all groups showed increased ethanol consumption compared with the AC phase (pb 0.001). Increased ethanol consumption was also observed after the second withdrawal cycle (aW2) compared with the other two cycles (aW3 and aW1) in all groups (pb 0.001).
The Kruskal-Wallis ANOVA performed for ethanol consumption in each phase revealed a statistically reliable main effect of group (AC: Individual examples of mice that exhibited differential patterns of ethanol consumption, expressed as a daily fluid intake average (mL). (A) A mouse from group A whose pattern indicates some degree of loss of control over ethanol ingestion, in which ethanol intake and preference are high throughout the acquisition phase, further increase after the withdrawal phase, and show no reduction when the drug is made less palatable through the addition of quinine (adulteration phase). (B) A mouse from group H which shows preference for ethanol throughout most of the weeks tested. The mouse, however, reduces ethanol intake and preference when ethanol solutions are adulterated with quinine. (C) A mouse from group L which exhibits preference for water over ethanol during all phases. Indeed, ethanol intake and preference remain low, regardless of the cycle of exposure, withdrawal, and reexposure to the drug. p b 0.01, respectively). Group A also consumed more ethanol than group L in aW2 cycle (p b 0.01) and more than group H in the AD phase (p b 0.05). Fig. 2 also shows the effect of baclofen treatment on ethanol consumption in the different groups. The Kruskal-Wallis analysis followed by the multiple comparison test for each group considering the three doses of baclofen and the saline-treated mice revealed that 1.25 mg/kg baclofen reduced significantly the ethanol intake in the group L (H 3, 114 =7.45, pb 0.05) compared with the saline-treated animals. The decrease in ethanol consumption in Group H did not reach statistical significance (H 3, 78 =4.44, p>0.05) and the group A maintained its ethanol intake under all doses of baclofen treatment (H 3, 76 =1.64, p> 0.05). Baclofen had no significant effect on ethanol consumption in the control group when the three doses were compared using the Friedman analysis (χ The multiple comparison test revealed that for the group H, the three doses reduced consumption compared to RE, the two higher doses increased intake compared to AD and the lower dose reduced consumption compared to AC and to the 2.5 mg/kg dose. For the group L, the two lower doses reduced intake compared to RE and the lower dose reduced intake compared to 2.5 mg/kg dose. For group A, a high ethanol intake was maintained during all phases and under baclofen treatment.
Ethanol consumption after baclofen administration
When we considered the three groups with saline treatment (nearly half of each group), we found that groups A and H returned to their ethanol intake patterns exhibited in the AC phase, but group L increased its ethanol consumption, suggesting an "alcohol deprivation effect" (ADE) (H 2, 160 = 24.79 p b 0.001).
Moreover, no difference was detected in ethanol consumption in the AC and AD phases when each baclofen-treated group was compared with each respective saline-treated group, suggesting that the random distribution of the mice to these two subgroups guaranteed homogeneity (Mann-Whitney test, p > 0.05).
Water consumption during 24 h period after baclofen administration
We also evaluated water consumption after baclofen treatment to verify whether its effect would be related to fluid consumption in general. The upper depicted graphic in Fig. 2 shows that the control group maintained their water intake along the phases and during the baclofen treatment. (χ 2 (11, 5) = 4.12, p = 0.66). Total ethanol intake over 24 h during the free choice model and the baclofen treatment. Data are expressed as median ± interquartile range of ethanol intake (g/kg/day). Ethanol consumption in the groups A, H and L during each experimental phase prior to baclofen treatment (AC, acquisition phase; aW1, after the first cycle of withdrawal phase; aW2, after the second cycle of withdrawal phase; aW3, after the third cycle of withdrawal phase; RE, reexposure phase; AD, adulteration phase). The vertical arrows represent the beginning of the period mice were treated with i.p. baclofen (B1.25, B2.5 and B5.0 are the doses of baclofen in mg/kg) or saline (SAL). During this period the half of the mice that were exposed only to water during the free-choice procedure (ethanol-naive control group) received also the three doses of baclofen and then, had free-choice between water and ethanol solutions in home-cage. The other half of the control group also received baclofen treatment but had only water in their home-cage (upper right inset). In this part of the figure, WW represents the median water consumption during all intervals between the ethanol withdrawal cycles when only water was available. The letters or numbers over the bars represent significant differences (L, from group L; H, from group H; AC, from acquisition phase; S, from the same group under saline (SAL) treatment; 2, from the 2.5 mg/kg of baclofen; 3, from the 5.0 mg/kg of baclofen; p b 0.05 at least; Kruskal-Wallis or Friedman tests followed by multiple comparison test). Fig. 3 . Ambulation in open field test -the bars represent the means ± standard errors of the ambulation in the central area (white) and in the peripheral area (gray) in mice exposed to the open field for 5 min. Each dose of baclofen (0.6; 1.25; 2.5; 5.0 and 10.0 mg/kg i.p.) or saline was administered 30 min before the test (n = 15 mice/ dose). The letters above the bars represent significant differences: S from the salinetreated mice; B0.6 from the 0.6 mg/kg baclofen-treated mice; B1.25 from the 1.25 mg/kg baclofen-treated mice; B2.5 from the 2.5 mg/kg baclofen-treated mice (ANOVA followed by Newman Keuls test, p b 0.05).
Body weight along the experiment
We evaluated the body weight of the different groups every week during all the experiment to calculate ethanol consumption in g/kg/day. ANOVA revealed no significant difference among the groups. Aiming to show that mice did not present differences in body weight among the different groups over the experiment, here we show the means and standard errors presented in the first week of the AC (group A: 31.5± 1.0; group H: 30.6± 0.8; group L: 31.9±0.7; group control: 30.1± 1.2; F 3, 58 =0.72 p=0.54), in the 16th week -last day of the AD phase (group A: 39.5± 1.6; group H: 39.1±1.1; group L: 42.0± 1.1; group control: 39.7 ± 1.4; F(3, 58)=1.25 p=0.30) and in the 20th week -last day of baclofen-treatment period (group A: 40.9± 1.2; group H: 40.1±1.3; group L: 43.8± 1.1; group control: 40.4± 1.0; F(3, 56)=2.29 p =0.09).
Discussion
The main finding of the present study was the demonstration of the differential effects of baclofen on ethanol consumption depending on intake profile in mice. Mice characterized as "loss of control" maintained their high ethanol intake under baclofen treatment. However, the lowest dose of baclofen reduced ethanol intake in "lightdrinkers". This same dose of baclofen also reduced ethanol intake in "heavy-drinkers" but only in relation to their own consumption in AC phase. As described earlier in the Introduction section, some inconsistencies are found regarding the baclofen effect on ethanol intake (Bechtholt and Cunningham, 2005; Colombo et al., 2000 Colombo et al., , 2002 Colombo et al., , 2003a Colombo et al., , 2003b Knapp et al., 2007; Maccioni et al., 2005 Maccioni et al., , 2008 Moore and Boehm, 2009; Walker and Koob, 2007; Czachowski et al., 2006; Petry, 1997; Smith et al., 1992 Smith et al., , 1999 Moore et al., 2007) . These discrepancies might be due to individual variability demonstrated here by the individual intake profile or due to different species, administration routes, procedures and doses of baclofen used.
Here, we raised the hypothesis that ethanol consumption observed in the present study, which are phenotypic manifestation, may have been related to genotypic differences among groups. This is because our previous study using the same paradigm (Ribeiro et al., 2010 (Ribeiro et al., , 2012 demonstrated that the genes that encode the GABA B1 and GABA B2 subunits were differentially expressed in mice that exhibited a "loss of control" profile just in brain areas which have been proposed by many authors (Kalivas and Volkow, 2005; Everitt and Robbins, 2005) to be related to addictive behavior. Ribeiro et al. (2010 Ribeiro et al. ( , 2012 demonstrated that animals from group A compared to the other two groups: had higher Gabbr1 and Gabbr2 transcription levels in the prefrontal cortex; lower Gabbr2 mRNA levels in the hippocampus and higher Gabbr1 transcription levels in the striatum. How these differences in transcription levels may account for differences in ethanol consumption is still unknown. Indeed, this was the main reason why we evaluated the effects of baclofen on ethanol consumption using this paradigm in the present study.
The mice from group A characterized in our model may have had disproportional expression of the two subunits as a result of the differential transcription levels found in the brain areas related to drug taking and drug seeking, suggesting a possible explanation for the lack of effect of baclofen in these mice. Even with baclofen treatment, these mice maintained their high ethanol intake and higher than the other two groups. From the phenotypic analysis, we inferred that the GABA agonist is efficient in reducing ethanol intake when the GABA B1 and GABA B2 subunits are effectively balanced. Some authors have demonstrated that conformational alteration of the GABA B1 subunit and subsequently conformational alteration of the entire GABA B1 -GABA B2 complex is necessary for effective activation of the GABA B receptor (Morishita et al., 1990) . Consequently, the precise balance between the two subunits is necessary for the activation of the receptor. One question is how this disproportional receptor subtype expression can support a basis for research on individualizing treatment. The present study has limitations, but our data highlight the importance for more studies to test this hypothesis because in humans it is also observed different ethanol drinking patterns and some medications are able to reduce ethanol intake only in some individuals (Johnson, 2010) . Indeed, Muzyk et al. (2012) in the recent systematic review proposed to test the baclofen effect on individuals with different ethanol intake patterns.
Our model is based on the three-bottle free-choice paradigm, with prolonged voluntary access to unsweetened ethanol solutions, where initially high consumption is alternated with days of near abstinence probably because mice are experiencing the pharmacological effects of the drug. During this acquisition phase, mice differently develop a characteristic pattern of consumption that remains stable for several weeks. Furthermore, during the withdrawal phases, the high-drinkers mice (groups A and H) might experience "anxiety"-related behaviors that could induce unpleasant effects and when ethanol is presented again its negative reinforcing properties may reduce anxiety (Koob and Le Moal, 1997) . Data analyzing "anxiety"-related behaviors are not shown here, but we have already demonstrated the manifestation of these behaviors during abstinence in other replications of the model (Correia et al., 2009; Fachin-Scheit et al., 2006; Ribeiro et al., 2008) . But, the most important characteristic of our model, which is determinant for the differentiation between groups A and H, is that quinine adulteration of the ethanol solution maintained ethanol consumption in the group A, but not in the groups H, suggesting that A mice seek ethanol despite the less-palatable tasting of quinine.
A limitation of the present model is that we did not verify whether group differences in drinking quinine adulterated ethanol are related to a higher motivation for ethanol or simply to differences in the perceived aversive qualities of quinine per se. However, some authors have also demonstrated the aversiveness of similar doses of quinine. For example, Hopf et al. (2010) showed that quinine taste preference, determined by home-cage two-bottle choice between water and water + quinine, had similar dose-response relationship in (1) rats that underwent 3-4 months of intermittent, home-cage, two-bottle access to 20% ethanol (v/v) or water, (2) animals with continuous access to ethanol, and (3) age-matched, ethanol-naive controls. Also, they showed a ceiling effect of reducing water intake in concentrations above 0.01 g/L of quinine. Whitney and Harder (1994) have already shown that quinine is aversive for mice at concentrations as low as 10 μM. Lesscher et al. (2010) demonstrated that when C57BL/6J mice, naturally high consumers, were exposed to limited access to ethanol solutions during a period of 8 weeks, they consumed an aversive, quinine-containing (from 250 μM) ethanol solution despite the simultaneous availability of an unadulterated ethanol solution.
Notably, each mouse consistently exhibits a persistent and characteristic individual intake pattern (here demonstrated by three examples) allowing the classification of mice into different groups. These different intake patterns could reflect differences in the vulnerability to the effects of ethanol, strengthening the relevance of the proposed model since one of the most prominent characteristics seen in humans is the great variability in the individual susceptibility to the development of dependence. In addition, this approach would allow the assessment of individualized treatment, which is a current tendency nowadays mainly for humans (Johnson, 2010) . Additionally, the model incorporates a "natural" development in the progression from initiation to "loss of control" of ethanol consumption (Sanchis-Segura and Spanagel, 2006) , which is observed only in some individuals. We previously demonstrated the model's reliability, which was replicated 10 times, and the same proportions of mice that exhibited the differential intake profiles were always found (about 18 to 25% are group A; 18 to 30% are group H and 28 to 35% are group L). The model has proven face validity, and also, has predictive validity when tested with naltrexone as a pharmacological challenge (Camarini et al., 2011; Correia et al., 2009; Fachin-Scheit et al., 2006; Ribeiro et al., 2008) . Besides, there is another benefit of developing such model in mice when comparing to existing rat models that is its shorter duration and lower cost.
Furthermore, another limitation in drinking studies has been that rodents, unlike humans, rarely consume ethanol to become intoxicated. Even those lines genetically selected for preference generally stop drinking when their BEC reaches about 50 to 70 mg% (Murphy et al., 1986) . However, some genetically rodent lines under certain conditions (Crabbe et al., 2009; Murphy et al., 2002; McBride and Li, 1998) voluntarily exceed BECs of 100 mg%, which is considered an intoxication level. In a similar study of our lab using the same model, we determined BEC levels at the end of the model (the day after AD phase). We observed that "loss of control" mice exhibited average BEC above this limit, i.e. 113 mg% while the "heavy drinker" mice showed 79 mg% and the "light drinker" mice showed 48 mg%. The BEC levels were positively correlated with the ethanol consumption presented at the end of the model (Ribeiro et al., 2012) .
In the present study, we modified the procedure of one of the phases compared with other studies previously performed in our lab (Correia et al., 2009; Fachin-Scheit et al., 2006; Ribeiro et al., 2008 Ribeiro et al., , 2010 Ribeiro et al., , 2012 . During the withdrawal phase in the previous studies, we used 2 weeks of prolonged abstinence, but the "alcohol deprivation effect" (ADE) was not consistently seen. The ADE, which was first described by Sinclair and Senter (1967) , defined as the temporary increase in voluntary ethanol intake that occurs in different animal species after a period of ethanol abstinence, has been proposed to model the compulsive, uncontrolled ethanol seeking and consuming behaviors that characterize ethanol relapse in human alcoholics (Boening et al., 2001; McBride et al., 2002) . Some authors suggested that the use of the ADE as a model of craving and/or relapse reflects the motivation that promotes the subsequent consumption of ethanol and can cause relapse based on the negative reinforcing properties of ethanol. Similarly, humans exhibit anxiety, depressed mood, and irritability during the ethanol withdrawal syndrome (Koob and Le Moal, 1997, 2001; Koob, 2000; Spanagel, 2003) . Wolffgramm et al. (2000) , using rats in a model similar to the present one, demonstrated that the ADE was related more to controlled consumption than to addiction. They reported that after several weeks of ethanol deprivation, the controlled drinkers, those that had not lost control over intake, consumed higher daily doses than before deprivation. In contrast, the loss of control animals maintained their high consumption of the drug. In the present study, we introduced multiple cycles of abstinence in an attempt to enhance "negative affect". We found that all mice exhibited significantly increase in ethanol intake after the withdrawal cycles compared with the AC phase (see Fig. 2 , aW1, aW2, and aW3 cycles in which the mice had access to ethanol after 4-day periods of withdrawal), suggesting the ADE. These findings suggest that at least in chronically drinking mice, the ADE represents a situation of increased motivation to seek and drink ethanol, which is compatible with the operational definition of craving (Markou et al., 1993) . However, although we have observed the ADE in all groups (A, H, and L) during the cycles of the withdrawal phase, in the period of baclofen or saline treatment only group L showed a nonsignificant (p =0.07) ADE, i.e. the controlled ones. This observation is in accordance to that reported by Wolffgramm et al. (2000) . Nevertheless, groups A, H and L when under saline treatment returned to their intake profile seen in AC phase confirming the internal reliability of the model. Tanchuck et al. (2011) reported that 5.0 mg/kg baclofen decreased binge ethanol consumption in mice but also tended to decrease water intake and significantly decreased operant sucrose selfadministration. In our study, baclofen had no effect on water consumption or on the body weight gain during the period mice were under baclofen treatment. Maybe baclofen did not interfere with consummatory behavior, as suggested by other authors (Anstrom et al., 2003) . Also, we can suggest that the baclofen effects observed in the present study perhaps occurred through a specific reduction in ethanol consumption rather than nonspecific sedative effects. This suggestion is based on the effects of five different doses of baclofen on locomotor activity tested in a naïve group of mice. From these data we chose the two doses (1.25 and 2.5 mg/kg) which did not change locomotor activity and the other dose (5.0 mg/kg) which was able to reduce locomotion in the open field test. The choice of the highest dose was just to test whether the effect on ethanol consumption was due to a depressant effect on its overall activity. If the sedative effect of baclofen was responsible for the decrease in consumption, then all animals (A, H and L) would have reduced consumption under the influence of 5 mg/kg. But, in the addiction model we demonstrated that only 1.25 mg/kg baclofen reduced ethanol intake in "light" and "heavy" drinkers but not in "addicted" and control groups. Importantly, one can expect that if the reduction in ethanol consumption induced by this dose was due to sedative effects, then, the higher dose (5.0 mg/kg) would cause more prominent sedation leading to higher reduction in ethanol consumption, which actually was not observed. Thus, these findings altogether indicated that the effect of 1.25 mg/kg baclofen was specific on ethanol consumption. Tanchuck et al. (2011) also described that baclofen was effective in reducing ethanol consumption up to 8 h after injection, i.e., this effect disappeared 10 h after the injection, suggesting that the timing of the baclofen injection and subsequent access to ethanol might be critical in determining how this drug affects ethanol intake, which was also proposed by other authors (Brebner et al., 2002; Moore et al., 2007; Shoaib et al., 1998) . In our study, we assessed ethanol consumption for 90 min, 30 min after baclofen treatment (data not shown here), and all groups showed minor changes in ethanol consumption after this period, but after 24 h the baclofen effect in reducing ethanol intake was observed. In the present study, the significant effect of the lowest dose of baclofen on group L, and a minor effect on group H, may suggest that mice of these two groups have consumed ethanol because of its reinforcing effects while group A was hypothesized to consume ethanol because of a "loss of control" in limiting intake, rendering the reinforcing properties of ethanol less relevant and then, abolishing the effects of baclofen. These observations were very similar to what we had suggested in our previous validation study using naltrexone when we found similar response profile in the three different groups (Fachin-Scheit et al., 2006) . The importance of several different neurochemical systems, including GABAergic and opioidergic systems, modulating ethanol's reinforcing and rewarding properties has been extensively studied (reviewed in Koob and Le Moal, 2006) . However, our explanations are only speculations requiring more studies.
Some evidence that may support this hypothesis is that GABA B receptor expression is proven to be most highly concentrated in the frontal cortex, hippocampus, and thalamus (Margeta-Mitrovic et al., 1999; Princivalle et al., 2001) . These regions are preferentially activated by cues paired with drug availability and use (Chang et al., 1994; Childress et al., 1999; George et al., 2001; Grant et al., 1996; Woodward et al., 1999) . Activity within these regions may provide a substrate for anticipatory behavioral states that precede actual drug use, and these states are not dependent on the acute or reinforcing actions of a drug. These neural mechanisms related to reinforcement that sustain behavioral activation states may be required for the initiation of responding for ethanol, natural reinforcers, and other drugs of abuse and may be disrupted in "loss of control" animals. Thus, the lack of effect of baclofen in group A mice raises the hypothesis that baclofen does not effectively alleviate the compulsive drive to use drugs that contributes to relapse and other drug-seeking states, which has also been suggested by other authors for animals and humans (Addolorato et al., 2002; Anstrom et al., 2003; Ling et al., 1998; Callahan et al., 1997; Lacey et al., 1988; Zaleski et al., 2001) .
In the present study, only the lowest dose of baclofen (1.25 mg/kg) showed a significant effect. Recent data indicate that only 2.5 mg/kg dose of baclofen selectively reduces binge drinking using the scheduled high ethanol consumption procedure in mice (Tanchuck et al., 2011) . However, in Tanchuck's study, mice have access to ethanol for a limited time (4-10 h for only a few days) in a binge drinking model. Also, Janak and Gill (2003) showed that rats that received 1 mg/kg baclofen reduced their ethanol self-administering, but 3 mg/kg had no effect.
Our results highlights the importance to study baclofen effect on different ethanol intake profiles in animals and maybe also in humans with different degrees of alcoholism.
